Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Global Fund

- PMLiVE

Pfizer wins new European approval for Prevenar 13

Expands use of pneumococcal disease vaccine to cover people aged 18 to 49

UK launch for Pfizer’s long-acting contraceptive injection Sayana

Becomes first contraceptive of its kind to reach the UK market

Synexus South Africa research sites join Pfizer trial network

CRO's sites become the first in Africa to meet the pharma company's standards

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

­Pfizer signs $635m deal with CytomX for cancer ADCs

Will use biotech's Probody technology to develop antibody-drug conjugates

- PMLiVE

Pfizer pulls late-stage trial of cancer drug in NHL

Inotuzumab ozogamicin fails to show survival benefit in phase III

- PMLiVE

Pfizer launches online home delivery service for Viagra

Partners with CVS/pharmacy on e-commerce initiative

- PMLiVE

Merck & Co and Pfizer join forces on diabetes candidate

Latest big pharma alliance involving an SGLT2 inhibitor

- PMLiVE

Pfizer cuts 2013 forecast after weak first quarter

Revenues down 9 per cent as key drugs face generic competition

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

- PMLiVE

EMA refuses to back Pfizer’s Xeljanz in rheumatoid arthritis

Surprise after approvals in US and Japan

- PMLiVE

Pfizer enters $210m+ nanomedicines deal with Bind

Will use Accurin technology to develop highly selective medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links